News
KEY INSTITUTIONAL INVESTOR SUPPORTS BNO CAPITAL RAISING
10-Feb-2009Key Points
- Cash position boosted upon exercise of BNOOB options
- IB Australia Bioscience Fund enters register
10 February 2009: Adelaide, Australia: Bionomics Limited (ASX:BNO) welcomes institutional investor, IB Australia Bioscience Fund, to its shareholder register. The specialist fund invested in Bionomics through subscription for listed BNOOB options last month.
Melbourne based biotech fund, IB Australian Bioscience Fund, was established in mid 2008 and is managed by Intersuisse Bioscience Managers Pty Ltd. The fund invests in both public and private companies that have internationally competitive healthcare technologies that are approaching pivotal clinical data milestones. Investors in the wholesale fund include industry superannuation funds, an institutional investment group, and highly regarded professional investors in the sector.
Matt McNamara, Chief Investment Officer, IB Australia Bioscience Fund, said "Bionomics is a quality stock and we are pleased to become major investors. With its strong management team and outstanding clinical pipeline, we believe Bionomics prospects are excellent.
$4,004,000 was raised through the options exercise, adding to the Company's cash balance of $4.3 million at 31 December 2008 and placing Bionomics in a strong position to pursue its clinical program. Cancer compound, BNC105, will enter Phase II development this year and regulatory submission will be lodged for lead anxiety compound, BNC210.
FOR FURTHER INFORMATION PLEASE CONTACT:
Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101
drathjen@bionomics.com.au
About Bionomics Limited
Bionomics (ASX: BNO) discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. Bionomics' most advanced program, BNC105 for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, the company's angiogenesis target and drug discovery platform, incorporates a variety of genomics tools to identify and validate novel angiogenesis targets. MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system..
For more information about Bionomics, visit www.bionomics.com.au
Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments, including, without limitation, statements made regarding BNC105, BNC210 and its' drug development programs are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward looking statements, including risks related to our available funds or existing funding arrangements, a further downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.
